SIGA Technologies Inc.
看多

SIGA - 2000% pump

130
In March 2022, the stock of SIGA Technologies saw a significant increase due to growing concerns about the monkeypox outbreak. The primary driver of this growth was the World Health Organization (WHO) declaring the monkeypox outbreak a global health emergency. This attracted investors' attention to the company, as its main product, the antiviral drug Tecovirimat (TPOXX), was developed to treat smallpox and has proven effective against monkeypox.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。